BioScience Health Innovations, Inc. (BHIC) operates a single segment focused on mental health and general wellness products, led by its clinically validated TPrime365 testosterone optimizer and emerging NAD+ restoration line. The latest 10-Q reveals steady progress in channel diversification including direct-to-consumer subscriptions, Amazon, wholesale, and strategic partnerships, complemented by efforts to establish a 503A compounding facility and expand internationally through Dubai registration. While BHIC’s proprietary MODS Max delivery system and patent-pending mitochondrial health technologies create a niche moat, the company faces capital constraints and competitive pressures typical of early-stage wellness firms. Anticipated catalysts include Nasdaq uplisting-driven governance upgrades and subscription program scaling, supported by a $1.15 million cash buffer heading into fiscal 2026.